Skip to content

A Randomized controlled Clinical Trial to determine the efficacy of Siddha drugs in COVID 19 patients

A Randomized controlled Clinical Trial to determine the complementary effect of selected Siddha formulations in facilitating the possibility of accelerated recovery in COVID 19 patients. - SIDCOVID

Status
Active, not recruiting
Phases
Phase 2Phase 3
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/06/025763
Enrollment
150
Registered
2020-06-09
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere

Interventions

Intervention1: Kabasura kudineer, Nilavembu kudineer, Amukra churnam, Thalisadhichurnam, Adathodai Manappagu, Brahmanada Bhairavam Pills, Thippili Rasayanam, Maldevi Chenduram, Adathodai Kudineer, Noc

Sponsors

National institute of Siddha
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Male, Female and Transgenders. ï?· Age between 18 to 85 years ï?· COVID 19 positive asymptomatic / pre symptomatic, mild and moderately and severely symptomatic patients. ï?· Willing to consent to the study.

Exclusion criteria

Exclusion criteria: High risk groups (Patients with Complications of Diabetes, Heart diseases, Cancer and Pregnancy) ï?· Multi organ failure Syndrome (MODS). ï?· Patients participating in other COVID 19 trials.

Design outcomes

Primary

MeasureTime frame
Primary Outcome would be measured through Reduction of symptoms and Recovery of patients from COVID 19 disease in a time bound manner.Conversion of RT PCR negative within first week of accelerated recoveryTimepoint: 6 months

Secondary

MeasureTime frame
Possible reduction of viral load data in subjects both at baseline and at 7 days, and 14 days or at recovery or 30 days whichever is earlier.. ï?· Number of days on treatment before recovery and Case fatality rate will also be noted. ï?· Reduction in Signs and symptoms like Fever, cough, breathlessness, and improvement in O2 saturation (SpO2) and PaO2/FiO2 becoming 300mg/Hg in patients with severe grade and ARDS.Timepoint: 6 MONTHS

Countries

India

Contacts

Public ContactDr P Shanmugapriya

National Institute of Siddha

mmssiddha@gmail.com9940266442

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026